Effects of chelation therapy on cardiac function improvement in thalassemia patients: Literature review and the Taiwanese experience

Hemoglobin

Volumn 32, Issue 1-2, 2008, Pages 49-62

  Peng, Ching Tien ^a,b   Tsai, Chang Hai ^a,b   Wu, Kang Hsi ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

Author keywords

Cardiac function; Glutathione S transferase M1 (GSTM1) gene; Iron chelator; Polymorphism; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; GLUTATHIONE TRANSFERASE M1; IRON;

BETA THALASSEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHELATION THERAPY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; GENETIC POLYMORPHISM; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK POPULATION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER LEVEL; MONOTHERAPY; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; PROGNOSIS; QUANTITATIVE ANALYSIS; SIDEROSIS; TAIWAN; THALASSEMIA; THALASSEMIA MAJOR; TREATMENT OUTCOME;

CARDIOMYOPATHIES; CHELATION THERAPY; DEFEROXAMINE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MYOCARDIUM; PYRIDONES; TAIWAN; THALASSEMIA;

EID: 39349093988     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260701680078     Document Type: Conference Paper

References (47)

1. Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with β-thalassemia major. Ann Hematol 2004; 83(12):779-783.
2. Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23(5):662-668.
3. Aessopos A, Deftereos S, Tsironi M, Karabatsos F, Yousef J, Fragodimitri C, Hatziliami A, Karagiorga M. Predictive echo-Doppler indices of left ventricular impairment in β-thalassemic patient. Ann Hematol 2007; 86(6): 429-434.
4. Roberts EB, Schafer F, Akhfur W, Patel D, Evans TR, Coghlan JG, Lipkin DP, Davar JI. Real-time myocardial contrast dobutamine stress echocardiography in coronary stenosis. Int J Cardiol 2006; 113(1):19-24.
5. Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from deferoxamine to deferiprone in β-thalassemia major patients. Hemoglobin 2006; 30(2):229-238.
6. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassemia major. Lancet 1989; 2(8653):27-30.
7. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220):2051-2052.
8. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineous E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73(5):359-366.
9. Weatherall DJ, Pippard MJ, Callender ST. Iron loading in thalassemia: five years with the pump. N Engl J Med 1983; 308(8):456-458.
10. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332(14):918-922.
11. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1): 1, iron chelation and metabolic studies. Br J Haematol 1990; 76(2):295-300.
12. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82(2):460-466.
13. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339(7):417-423.
14. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long term trial of deferiprone in 51 transfusion dependent iron overloaded patients. Blood 1998; 91(1):295-300.
15. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332):516-520.
16. Piga A, Gagliotic C, Fogliacco E, Tricta F. Comparative effects of deferioprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88(5):489-496.
17. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9):3738-3744.
18. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107(9):3733-3737.
19. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23):2171-2179.
20. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Hematologica 2004; 89(10):1187-1193.
21. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95(1):26-36.
22. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. Br J Haematol 2000; 110(4):971-977.
23. Olivieri NF, Nathan DG, MacMillan JH, Wayne AD, Martin M, McGee A, Koren G, Liu PP, Cohen AR. Survival of medically treated patients with homogygous β thalassemia. N Engl J Med 1994; 331(9):574-578.
24. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331(9):567-573.
25. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: patients with homozygous β-thalassaemia and transfusional iron overload. Br J Haematol 1980; 46(3):409-416.
26. Kolnagou A, Economides C, Eracleous E, Kontoghioghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2):219-227.
27. Wood JC, Tyszka M, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103(5):1934-1936.
28. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70(6):392-397.
29. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regress severe heart failure in patients with β-thalassemia major. Ann Hematol 2004; 83(7):471-473.
30. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, GiakoumisA, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007; 92(1):131-132.
31. Pippard MJ, Warner GT, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in β-thalassaemia intermedia. Lancet 1979; 2(8147):819-821.
32. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343(5):327-331.
33. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 14-34.
34. Desferal R Product Monograph. Novartis Inc., 1998, Basel, Switzerland.
35. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, refractory anemia with hemochromatosis. Circulation 1964; 30(5):698-705.
36. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104(1):263-269.
37. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3):348-355.
38. Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with β-thalassemia major. Hemoglobin 2006; 30(2):251-256.
39. Peng CT, Wu KH, Wu SF, Liang DC, Yang CP, Jang RC, Wang LY, Hsiao CC. Deferiprone or deferoxamine versus combination therapy in patients with β-thalassemia major: a case study in Taiwan. Hemoglobin 2006; 30(1):125-130.
40. Abstract Book: 15th International Conference on Oral Chelation in The Treatment of Thalassemia and Other Diseases. Taichung, Taiwan, 22-26 April 2005.
41. Grady RW, Berdoukas V, Rachmilewitz EA. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion. Blood 2002; 100(Suppl 1):241.
42. Olivieri NF. The β-thalassemias. N Engl J Med 1999; 341(2):99-109.
43. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99(1):36-43.
44. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97(11):3411-3416.
45. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350(9):886-895.
46. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995; 86(5):2008-2013.
47. Peng CT, Fucharoen S, Kontoghiorghes GJ, Tsai CH. Report on the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases in Taichung, Taiwan, 22-26 April, 2005. Hemoglobin 2006; 30(1):63-68.